Literature DB >> 17235696

The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Erin M MacKenzie1, John Odontiadis, Jean-Michel Le Mellédo, Trevor I Prior, Glen B I Baker.   

Abstract

1. Neuroactive steroids are steroid hormones that exert rapid, nongenomic effects at ligand-gated ion channels. There is increasing awareness of the possible role of these steroids in the pathology and manifestation of symptoms of psychiatric disorders. The aim of this paper is to review the current knowledge of neuroactive steroid functioning in the central nervous system, and to assess the role of neuroactive steroids in the pathophysiology and treatment of symptoms of schizophrenia, depression, and anxiety disorders. Particular emphasis will be placed on GABAA receptor modulation, given the extensive knowledge of the interactions between this receptor complex, neuroactive steroids, and psychiatric illness. 2. A brief description of neuroactive steroid metabolism is followed by a discussion of the interactions of neuroactive steroids with acute and chronic stress and the HPA axis. Preclinical and clinical studies related to psychiatric disorders that have been conducted on neuroactive steroids are also described. 3. Plasma concentrations of some neuroactive steroids are altered in individuals suffering from schizophrenia, depression, or anxiety disorders compared to values in healthy controls. Some drugs used to treat these disorders have been reported to alter plasma and brain concentrations in clinical and preclinical studies, respectively. 4. Further research is warranted into the role of neuroactive steroids in the pathophysiology of psychiatric illnesses and the possible role of these steroids in the successful treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235696     DOI: 10.1007/s10571-006-9086-0

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  267 in total

1.  A PRELIMINARY INVESTIGATION OF STEROID EXCRETION IN DEPRESSED PATIENTS BEFORE AND AFTER ELECTROL-CONVULSIVE THERAPY.

Authors:  H C FERGUSON; A C BARTRAM; H C FOWLIE; D M CATHRO; K BIRCHALL; F L MITCHELL
Journal:  Acta Endocrinol (Copenh)       Date:  1964-09

Review 2.  Social isolation stress-induced aggression in mice: a model to study the pharmacology of neurosteroidogenesis.

Authors:  Kinzo Matsumoto; Graziano Pinna; Giuli Puia; Alessandro Guidotti; Erminio Costa
Journal:  Stress       Date:  2005-06       Impact factor: 3.493

3.  Double-blind treatment of major depression with dehydroepiandrosterone.

Authors:  O M Wolkowitz; V I Reus; A Keebler; N Nelson; M Friedland; L Brizendine; E Roberts
Journal:  Am J Psychiatry       Date:  1999-04       Impact factor: 18.112

4.  The action of stress, beta-carbolines, diazepam, and Ro 15-1788 on GABA receptors in the rat brain.

Authors:  G Biggio
Journal:  Adv Biochem Psychopharmacol       Date:  1983

5.  Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

Authors:  I Sundström; A Andersson; S Nyberg; D Ashbrook; R H Purdy; T Bäckström
Journal:  Neuroendocrinology       Date:  1998-02       Impact factor: 4.914

6.  Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

Authors:  Peter J Schmidt; Robert C Daly; Miki Bloch; Mark J Smith; Merry A Danaceau; Linda Simpson St Clair; Jean H Murphy; Nazli Haq; David R Rubinow
Journal:  Arch Gen Psychiatry       Date:  2005-02

7.  Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats.

Authors:  D C de Goeij; R Kvetnansky; M H Whitnall; D Jezova; F Berkenbosch; F J Tilders
Journal:  Neuroendocrinology       Date:  1991-02       Impact factor: 4.914

8.  Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.

Authors:  Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman
Journal:  Arch Gen Psychiatry       Date:  2003-02

9.  [GABA levels in the plasma of patients with endogenous depression and during the treatment with thymoleptics].

Authors:  A Rode; A Bidziński; S Puzyński
Journal:  Psychiatr Pol       Date:  1991 May-Aug       Impact factor: 1.657

10.  Functional correlation between allopregnanolone and [35S]-TBPS binding in the brain of rats exposed to isoniazid, pentylenetetrazol or stress.

Authors:  A Concas; M C Mostallino; C Perra; R Lener; G Roscetti; M L Barbaccia; R H Purdy; G Biggio
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

View more
  15 in total

Review 1.  Childhood stressful events, HPA axis and anxiety disorders.

Authors:  Carlo Faravelli; Carolina Lo Sauro; Lucia Godini; Lorenzo Lelli; Laura Benni; Francesco Pietrini; Lisa Lazzeretti; Gabriela Alina Talamba; Giulia Fioravanti; Valdo Ricca
Journal:  World J Psychiatry       Date:  2012-02-22

2.  Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia.

Authors:  HuaLin Cai; Xiang Zhou; George G Dougherty; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Matcheri Keshavan; Jeffrey K Yao
Journal:  Psychoneuroendocrinology       Date:  2018-02-07       Impact factor: 4.905

Review 3.  Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date.

Authors:  Vladimir Lerner; Peter J A McCaffery; Michael S Ritsner
Journal:  CNS Drugs       Date:  2016-04       Impact factor: 5.749

4.  Impaired neurosteroid synthesis in multiple sclerosis.

Authors:  Farshid Noorbakhsh; Kristofor K Ellestad; Ferdinand Maingat; Kenneth G Warren; May H Han; Lawrence Steinman; Glen B Baker; Christopher Power
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

5.  A genomewide linkage scan of cocaine dependence and major depressive episode in two populations.

Authors:  Bao-Zhu Yang; Shizhong Han; Henry R Kranzler; Lindsay A Farrer; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2011-08-17       Impact factor: 7.853

6.  Diurnal cortisol amplitude and fronto-limbic activity in response to stressful stimuli.

Authors:  Amy C Cunningham-Bussel; James C Root; Tracy Butler; Oliver Tuescher; Hong Pan; Jane Epstein; Daniel S Weisholtz; Michelle Pavony; Michael E Silverman; Martin S Goldstein; Margaret Altemus; Marylene Cloitre; Joseph Ledoux; Bruce McEwen; Emily Stern; David Silbersweig
Journal:  Psychoneuroendocrinology       Date:  2009-01-09       Impact factor: 4.905

7.  Pregnanolone sulfate promotes desensitization of activated NMDA receptors.

Authors:  Cassandra L Kussius; Navjot Kaur; Gabriela K Popescu
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

8.  Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides.

Authors:  Jean Luc Do Rego; Jae Young Seong; Delphine Burel; Jerôme Leprince; David Vaudry; Van Luu-The; Marie-Christine Tonon; Kazuyoshi Tsutsui; Georges Pelletier; Hubert Vaudry
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-24       Impact factor: 5.555

9.  The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.

Authors:  Emily Hayes; Emorfia Gavrilidis; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-02-19

10.  Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques.

Authors:  Jeffrey M Milush; Hui-Ling Chen; Ginger Atteberry; Donald L Sodora
Journal:  Front Immunol       Date:  2013-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.